$1.2 M

CYTX Mkt cap, 22-Jun-2018
Cytori Therapeutics Net income (Q1, 2018)-4.4 M
Cytori Therapeutics EBIT (Q1, 2018)-4.4 M
Cytori Therapeutics Cash, 31-Mar-20185.9 M

Cytori Therapeutics Financials

Cytori Therapeutics Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

7.1 m5 m4.8 m4.7 m

Revenue growth, %

(30%)(2%)(4%)

Cost of goods sold

3.4 m2.9 m3.2 m2.7 m

Gross profit

3.7 m2 m1.7 m1.9 m

Gross profit Margin, %

52%41%34%42%

Sales and marketing expense

9 m6.4 m2.7 m3.6 m3.6 m

R&D expense

17.1 m15.1 m19 m16.2 m11.7 m

General and administrative expense

16 m16 m9.8 m8.6 m7.6 m

Operating expense total

42.1 m37.5 m31.4 m28.4 m24.6 m

Depreciation and amortization

1.2 m

EBIT

(30.7 m)(32.4 m)(15.3 m)(19.7 m)(20.7 m)

EBIT margin, %

(431%)(655%)(316%)(423%)

Interest expense

3.4 m4.4 m3.4 m2.6 m2 m

Interest income

4 k6 k9 k19 k33 k

Net Income

(26.2 m)(37.4 m)(18.7 m)(22 m)(22.7 m)

Quarterly

USDQ1, 2018

Sales and marketing expense

678 k

R&D expense

2.5 m

General and administrative expense

2.2 m

Operating expense total

5.4 m

Depreciation and amortization

306 k

EBIT

(4.4 m)

Interest expense

423 k

Interest income

14 k

Net Income

(4.4 m)

Cytori Therapeutics Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

15.5 m14.6 m14.3 m12.6 m9.6 m

Accounts Receivable

Inventories

3.7 m3.2 m

Current Assets

24.6 m21.7 m21.2 m18.7 m14.9 m

PP&E

1.1 m1.6 m1.6 m1.2 m3.1 m

Goodwill

3.9 m3.9 m3.9 m3.9 m3.9 m

Total Assets

42.1 m38.7 m37.7 m34.6 m31.6 m

Accounts Payable

6.1 m5.5 m6.7 m5.9 m4.8 m

Short-term debt

Current Liabilities

14.9 m15.9 m8.4 m12.5 m18.4 m

Long-term debt

Total Liabilities

23.6 m18.6 m

Additional Paid-in Capital

303.7 m331.8 m368 m388.8 m413.3 m

Retained Earnings

(300.9 m)(338.3 m)(357 m)(379.1 m)(401.7 m)

Total Equity

3.1 m11 m13 m

Financial Leverage

13.4 x3.2 x2.4 x

Quarterly

USDQ1, 2018

Cash

5.9 m

Inventories

3.2 m

Current Assets

10.7 m

PP&E

2.9 m

Goodwill

3.9 m

Total Assets

26.6 m

Accounts Payable

4.2 m

Current Liabilities

17.9 m

Total Liabilities

18.2 m

Additional Paid-in Capital

413.5 m

Retained Earnings

(406.2 m)

Total Equity

8.5 m

Financial Leverage

3.1 x

Cytori Therapeutics Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(26.2 m)(37.4 m)(18.7 m)(22 m)(22.7 m)

Depreciation and Amortization

1.6 m779 k1.1 m1.2 m2.2 m

Accounts Receivable

(1.2 m)2.1 m328 k(179 k)1.1 m

Inventories

(459 k)(815 k)490 k471 k251 k

Accounts Payable

(409 k)(1.1 m)1 m(673 k)(1.8 m)

Cash From Operating Activities

(34.6 m)(30.3 m)(20.5 m)(19.5 m)(18.1 m)

Purchases of PP&E

(519 k)(764 k)(611 k)(67 k)

Cash From Investing Activities

3.7 m(1.3 m)(613 k)64 k(1.7 m)

Dividends Paid

(75 k)

Cash From Financing Activities

20.8 m30.9 m20.8 m17.6 m16.8 m

Interest Paid

2.3 m2.6 m2 m1.6 m1.4 m

Quarterly

USDQ1, 2018

Net Income

(4.4 m)

Depreciation and Amortization

497 k

Accounts Receivable

(747 k)

Inventories

141 k

Accounts Payable

(556 k)

Cash From Operating Activities

(4.1 m)

Cash From Investing Activities

(53 k)

Cash From Financing Activities

(150 k)

Interest Paid

311 k

Cytori Therapeutics Ratios

USDY, 2018

Financial Leverage

3.1 x
Report incorrect company information